logo
logo

Cellecta, Inc.


Cellecta provides contract research services for the discovery and characterization of novel drug targets, and the development of novel therapeutics.

Cellecta’s genome-wide and targeted RNAi screening platform, which combines complex lentiviral shRNA expression libraries with HT sequencing, enables identification of genes regulating a variety of cellular responses and possible therapeutic targets and helps researchers identify new targets, prioritize known targets, characterize therapeutic mechanisms of action, and identify genes that induce an additive or synergistic response.

The approach is particularly useful in elucidating the mechanism of action for compounds and for investigators interested in identifying essential genes in cancer models.